Back to blog
46 thumb

Chronomics Secures £1.12 million in Seed Funding

We are delighted to announce that epigenetics biotech company Chronomics has successfully secured more than £1.12 million in funding. This investment will act as a major catalyst for growth, helping us to revolutionise attitudes towards health management and achieve our vision of a world where everyone can manage and action their own health.

Our CEO and Founder Dr Tom Stubbs was understandably thrilled at the news, declaring, “Reaching £1.12 million in seed funding is a momentous milestone for Chronomics, having just launched the company last year. Receiving the support of prominent backers reflects their confidence in our company, and our vision.”

The investment has come from two of the world’s leading venture capital firms. The first, Anthemis, a venture investment and advisory firm dedicated to cultivating change in financial services, has provided significant investment. Here’s what Anthemis’ Vica Manos had to say about us: “The team is combining a brand-new data source and cutting-edge science to help consumers make better, more informed decisions about their lifestyle, which is really exciting. We are delighted to support the Chronomics team as they gear up for the next phase of their journey.”

SOSV, one of the world’s most active early stage biotech investors and all around awesome people, initially invested in Chronomics through the RebelBio programme after reviewing 350 companies, and have now continued their unwavering support by providing follow-on investment.

Chronomics also secured funding from leading angel investors, including Laurence Garrett, senior partner with Highland Europe. Laurence has significant experience as a private investor in AI and deep tech companies, such as Speechmatics and FeatureSpace, and was previously on the board of BlueGnome Ltd., a pioneer in gene testing to improve IVF success rate.

Laurence had some more good things to say: “The Chronomics team are academically exceptional. The company has responded to an increased desire amongst people to improve the quality of their lives through sound scientific data about their epigenetic profile. I am grateful to Tom and the team to allow me to become an investor in their business.”

Through their funding our investors have been given the unique opportunity to help revolutionise the way people think about healthcare with Chronomics, supporting individuals to take control of their DNA and make proactive choices towards a better, healthier life. This is just the beginning - sign up to our newsletter and follow us on social to hear about more exciting developments as they happen.

Back to blog


Enter your email address to keep up to date with the latest Chronomics news.

discover how

The Chronomics Epigenetic Test is the first test in the world that allows you to sample the epigenetic information in your DNA in order to improve your health and wellness